 BOSTON, April 26, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will give the keynote presentation at the Mitochondria-Targeted Drug Development Digital Summit on Wednesday, April 28, 2021. In addition, Stealth will be presenting an abstract demonstrating the power of longitudinal natural history data in ultra-rare diseases in evaluating and validating clinical trial outcomes. 